Home  /  Scientific & Medical Writing  /  Clinical Trial Protocol Writing
Scientific & Medical Writing · ICH E6 GCP

Clinical Trial Protocol Writing Services

The protocol is the foundation of your trial. It defines the objectives, design, endpoints, eligibility, statistics, and safety monitoring that everything downstream depends on. EvySaif's clinical trial protocol writing services produce clear, scientifically rigorous, GCP-aligned protocols for Phase 1 through Phase 4 studies, written to satisfy ethics committees and regulators in India and internationally.

ICH E6(R3)ICH E8(R1)NDCT 2019Phase 1 to 4
Protocol · Build
SynopsisEarly design alignment
ProtocolObjectives, endpoints, statistics
ConsentICDs written for comprehension
ApprovalIEC and CDSCO ready
The Pathway

Built on current GCP and design guidance

Our protocols are written in line with ICH E6 Good Clinical Practice, including the updated E6(R3) principles, and ICH E8(R1) on general considerations for clinical studies, with a risk-based, quality-by-design approach to the factors that matter most for your trial.

Design to current GCP

ICH E6 GCP including E6(R3), and ICH E8(R1), applied with a risk-based, quality-by-design approach rather than as a checklist.

ICH E6(R3)ICH E8(R1)

Build in the India requirements

For studies running in India, we build in the specific requirements of the New Drugs and Clinical Trials Rules, 2019: compensation provisions, serious adverse event reporting timelines, and Institutional Ethics Committee (IEC) expectations.

NDCT 2019CompensationSAE timelines

Prepare for submission and registration

The dossier components needed for CDSCO submission via Form CT-04 and the SUGAM portal, alongside IEC and CTRI registration requirements.

Form CT-04SUGAMCTRI

Keep the language consistent downstream

We keep the protocol, synopsis, ICF, and downstream CSR language consistent from the start. A well-designed protocol reduces amendments, smooths ethics approval, and keeps your endpoints and statistics aligned from day one.

At a Glance
StandardsICH E6 GCP, including E6(R3)
Design guidanceICH E8(R1)
India frameworkNDCT Rules, 2019
Trial phasesPhase 1 to 4
India submissionForm CT-04 via SUGAM
EthicsIEC and CTRI registration

Genuine early-phase experience: EvySaif has authored real Phase 1 clinical trial protocols, including first-in-human buccal-route designs developed under India's NDCT 2019 framework. Early-phase work demands particular care around dose rationale, safety monitoring, and stopping rules.

Deliverables

What we prepare

Full clinical trial protocolsFor interventional studies, Phase 1 to 4.

Protocol synopsisFor early design alignment and regulatory pre-submission.

Informed consent documentsICDs and ICFs written for participant comprehension and IEC approval.

BA and BE protocolsBioavailability and bioequivalence study protocols.

Early-phase and first-in-humanWith appropriate safety and dose-escalation design.

CDSCO and NDCT 2019 alignmentCompensation, SAE timelines, IEC, and CTRI registration requirements.

Partnership

How EvySaif helps

We do not just transcribe a concept. We pressure-test the endpoints, eligibility, and safety design against what ethics committees and regulators will actually ask, build in the India-specific requirements where they apply, and keep the protocol, synopsis, ICF, and downstream CSR language consistent from the start.

Design to ICH E6 GCP and E8(R1)
Build in NDCT 2019 requirements where they apply
Write IEC-ready consent documents alongside the protocol
Keep protocol, synopsis, ICF, and CSR language aligned

Why EvySaif

EvySaif ranks among the best research and medical writing consultancies in India. Protocol writing here is clinician-led and design-aware. We do not just transcribe a concept, we pressure-test the endpoints, eligibility, and safety design against what ethics committees and regulators will actually ask. We keep the protocol, synopsis, ICF, and downstream CSR language consistent from the start, and we deliver at consultancy pricing suited to emerging sponsors.

Questions

Frequently asked questions

ICH E6 GCP (including E6(R3)) and ICH E8(R1), plus India's New Drugs and Clinical Trials Rules, 2019 for CDSCO submissions, and ICMR ethical guidelines where applicable.

Yes. This is a demonstrated strength, including early-phase designs prepared under the NDCT 2019 framework.

Yes. We write IEC-ready ICDs and ICFs alongside the protocol, in plain language for participant comprehension.

We align the protocol and supporting documents with CDSCO and NDCT 2019 expectations, including compensation provisions, SAE timelines, and IEC coordination.

Have a different question?

Tell us about your product, market, and timeline, and a clinician on our team will reply with specifics rather than a sales script.

Request a proposal
Last updated: July 2026. Regulatory forms, portals, and timelines change; specifics are re-verified periodically.

Designing a study?

Tell us about your compound, phase, and timeline, and we will come back with a scoped protocol writing quote.

Request a proposal